Burlington, MA – According to filings with the U.S. Securities and Exchange Commission, RedShift BioAnalytics is raising $6,444,632.00 in new funding. Sources indicate as part of senior management President, Charles Marshall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RedShift BioAnalytics

RedShiftBio provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality.

To learn more about RedShift BioAnalytics, visit http://redshiftbio.com/

Contact:
Charles Marshall, President
781-345-7300
cmarshall@redshiftbio.com
https://www.linkedin.com/in/chipm/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved